- Bausch + Lomb recently released findings from its third annual State of Dry Eye survey, showing that dry eye symptoms materially affect emotional health and that prescription treatments tend to deliver stronger improvements in wellbeing and productivity than over-the-counter products.
- The survey also revealed that many people with dry eye are unaware of links to broader health conditions such as autoimmune diseases and menopause, underscoring a potential gap in diagnosis and treatment discussions.
- We’ll now examine how this new evidence on dry eye’s emotional impact and prescription treatment benefits could influence Bausch + Lomb’s investment narrative.
Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
Bausch + Lomb Investment Narrative Recap
To own Bausch + Lomb, you need to believe that its broad eye health platform, especially in dry eye, can eventually translate into sustainable revenue growth and improving profitability despite current losses. The new State of Dry Eye survey strengthens the medical and emotional case for prescription treatments, but it does not materially change the near term catalysts around execution in Pharma and Vision Care, nor the key risk of weak returns on invested capital and ongoing losses.
Among recent announcements, the upgraded 2026 revenue guidance to US$5.420 billion to US$5.520 billion is most relevant here. It frames how management already sees underlying demand, including in dry eye, before factoring in any potential incremental benefit from heightened awareness or prescription uptake suggested by the survey. For investors, the question is whether this kind of data can support that guidance over time, while the company works to narrow losses and improve free cash flow.
Yet beneath this opportunity, there is still the risk that Bausch + Lomb’s low returns on invested capital and rising capital intensity could...
Read the full narrative on Bausch + Lomb (it's free!)
Bausch + Lomb's narrative projects $6.2 billion revenue and $265.5 million earnings by 2029. This requires 5.9% yearly revenue growth and an earnings increase of about $484.5 million from -$219.0 million today.
Uncover how Bausch + Lomb's forecasts yield a $17.88 fair value, a 8% upside to its current price.
Exploring Other Perspectives
Some of the most optimistic analysts already assumed revenue reaching about US$6.0 billion and earnings near US$243 million by 2028, which is far more upbeat than consensus and could look either more achievable or more stretched once the emotional and medical weight of dry eye from this survey is fully reflected in updated views.
Explore 5 other fair value estimates on Bausch + Lomb - why the stock might be worth just $17.88!
The Verdict Is Yours
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Bausch + Lomb research is our analysis highlighting 3 key rewards that could impact your investment decision.
- Our free Bausch + Lomb research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Bausch + Lomb's overall financial health at a glance.
Seeking Other Investments?
These stocks are moving-our analysis flagged them today. Act fast before the price catches up:
- Find 41 companies with promising cash flow potential yet trading below their fair value.
- Capitalize on the AI infrastructure supercycle with our selection of the 53 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
- AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com